钠-葡萄糖协同转运蛋白2抑制剂在腹膜透析中的研究及应用前景

Sodium-glucose co-transporter 2 inhibitors in peritoneal dialysis patients

钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)作为一种新型口服降糖药,对2型糖尿病或非糖尿病患者都表现出良好的心肾保护作用,并可改善慢性肾脏病患者的心肾结局。虽然目前临床试验已将纳入人群的估算肾小球滤过率(eGFR)扩展至更低水平,但仍排除了eGFR<20 mL/(min·1.73 m 2)的患者,SGLT2i的心肾保护作用能否延续至维持性透析期是临床关注的重点。此外,SGLT2i的抗炎和抗纤维化作用可能对腹膜透析(PD)患者维持腹膜功能有益。因此,SGLT2i在PD患者中的应用值得进一步探索。

Sodium-glucose co-transporter 2 inhibitors(SGLT2i),a novel type of oral antihyperglycaemic drugs,have demonstrated favorable cardiorenal protective effects in patients with type 2 diabetes or non-diabetic individuals.They can also improve cardiorenal outcomes in patients with chronic kidney disease.Although clinical trials have expanded the inclusion criteria for estimated glomerular filtration rate(eGFR)to lower levels,patients with eGFR<20 ml/min/1.73m^2 are still excluded.Whether the continuation of cardiorenal protective effects of SGLT2i during the maintenance dialysis phase is an area of clinical focus.Additionally,the anti-inflammatory and anti-fibrotic properties of SGLT2i may benefit the preservation of peritoneal function in patients undergoing peritoneal dialysis(PD).Therefore,further exploration of the application of SGLT2i in PD patients is warranted.